2010 News Releases
Dec 24, 2010:
iCo Therapeutics Extends Investor Relations Engagement with The Trout Group
Dec 8, 2010:
iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus Royalties
Nov 26, 2010:
iCo Therapeutics Reports Third Quarter 2010 Financial Results
Oct 13, 2010:
iCo Therapeutics Selected as Canada's Top 10TM Competition Winner
Sep 29, 2010:
iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status
Sep 22, 2010:
iCo Therapeutics Appoints Infectious Disease Experts to Scientific Advisory Board
Aug 27, 2010:
iCo Therapeutics Announces Second Quarter 2010 Financial Results
Jul 26, 2010:
iCo Therapeutics Inc. receives Health Canada Clearance to Conduct Phase II DME Trial with iCo-007
May 28, 2010:
iCo Therapeutics Inc. enters into Investor Relations Engagements with The Trout Group and Sector Speak
May 26, 2010:
iCo Therapeutics Announces First Quarter 2010 Financial Results
May 25, 2010:
iCo Therapeutics Inc. enters into Technology Transfer Agreement with Isis Pharmaceuticals, Inc. for iCo-007
May 17, 2010:
iCo Therapeutics iCo-007 Phase I Clinical Trial Meets Primary Endpoint
Apr 29, 2010:
iCo Therapeutics Announces Year-End 2009 Financial Results
Apr 28, 2010:
iCo Therapeutics Inc. engages Susan Koppy to spearhead iCo-007 out-licensing
Apr 22, 2010:
iCo-007 for Diffuse Diabetic Macular Edema to be Presented at Retinal Physician Symposium 2010
Apr 12, 2010:
iCo Therapeutics Inc. Recognized by BIOTECanada with Gold Leaf Award
Feb 19, 2010:
iCo-007 for Diabetic Macular Edema to be Presented at Angiogenesis 2010: Clinical Trials
Feb 10, 2010:
iCo Therapeutics Announces Exercise of Warrants
Copyright 2010 ICO Therapeutics | Disclaimer